Is Pharma Research Doing Enough for Diabetes?

With prediabetes and type 2 on the rise in the U.S., are pharma companies doing enough to develop new treatments? Harvard researchers argue that companies are doing less R&D into diabetes drugs than would be expected given the prevalence of the disease, and suggest FDA requirements to determine the cardiovascular safety of new drugs may […]

Osteoporosis and Diabetes

When it comes to increased risk of osteoporosis, not all diabetes drugs are the same. A new study looks at the connections between diabetes and osteoporosis, and suggests certain types of drugs should be avoided to reduce risk of bone loss. Read more

Can Metformin Really Slow Aging?

The diabetes drug metformin is reputed to have many beneficial effects. Researcher Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine in the Bronx, New York, believes it may be able to help us extend our years of healthy, illness-free life. Read more.

A New Solution for Monitoring Insulin Temperature

Amin Zayani has had type 1 diabetes for 11 years and relies on daily insulin injections. A couple of years ago he had a bad experience when his insulin suddenly seemed to stop working. He discovered that the cause was that, unknown to him, his insulin had frozen in the refrigerator, ruining its potency. To keep […]

Diabetes Drug Canagliflozin Shows Heart Benefits

Canagliflozin (marketed under the brand name Invokana) is one of a newer class of diabetes drugs, the SGLT-2 Inhibitors, that have received much attention in the last few years.  Now a new study shows that patients taking canagliflozin have a significantly reduced risk of heart attacks and strokes when compared to placebo. Since most patients […]

Diabetes Drug Shows Benefits for Heart & Kidney Disease

A new study from Australia reports that the diabetes drug canagliflozen may have benefits beyond lowering blood sugar in patients with type 2 diabetes. It also may lower the risk of cardiovascular disease (CVD) and kidney disease significantly. Read more

Can Liraglutide Prevent Diabetes?

A new study found the diabetes drug liraglutide performed better than placebo in reducing the risk that patients with prediabetes would progress to type 2 diabetes, when combined with a program of diet, exercise and weight loss. Read more

New UK Guidelines Raise Prominence of SGLT-2 Inhibitors

The UK National Institute of Health and Care Excellence (NICE) has revised its type 2 diabetes guidelines to give more prominence to sodium-glucose cotransporter 2 (SGLT-2) inhibitor drugs as a treatment option. While a warning about the association of these drugs with diabetic ketoacidosis (DKA) remains, the guidelines offer stronger support of these drugs as treatments. Currently […]

Roche Offers New Discount Program

Major pharma company Roche has made changes to its blood glucose monitoring system and introduced a new discounting offer, which is says could save uninsured diabetes patients thousands of dollars per year. This may be aimed to address the scrutiny drug companies are receiving over pricing, including the cost of insulin. Read more

A New FDA Warning for Diabetes Drug

The FDA has issued a new warning for the type 2 diabetes medicine canagliflozin (offered under the brand names Invokana, Invokamet, and Invokamet XR). Two large clinical trials have indicated the drug carries an increased risk of leg and foot amputations. The FDA advises patients taking canagliflozin to immediately notify their doctor if they experience new pain […]

The Financial Burden of Diabetes

Patients with diabetes sometimes don’t take their medications — including insulin — consistently or at the correct dose. How much of this “noncompliance” is due to financial concerns? A new study looks at the financial burden of out-of-pocket costs for patients with diabetes, and at how inability to afford medication impacts the choices diabetics make. Read more

Victoza Tested as Add-on Therapy for DKA in Type 1

A recent study has looked into whether Victoza and other drugs in its class (GLP-1 agonists) can help people with type 1 diabetes to lower their blood glucose levels and lower risk of diabetic ketoacidosis (DKA). The study, conducted by researchers at the Diabetes and Endocrinology Center of Western New York, investigated whether Victoza could reduce production […]

Where are all the new diabetes drugs?

So has pharma run out of ideas in diabetes? Not exactly. But whether its ideas will ever get to market is another question. There’s plenty of promising science in the early stages of research. Available drugs, however, work pretty well. Given the cost of development and a high bar for approval, pharma can only afford […]

A New Combination Treatment Could Become the Standard T2 Diabetes

A study in Diabetes Care showed that patients with poorly controlled type 2 diabetes who received a combination of exenatide and pioglitazone had a threefold lower rate of hypoglycemia, a one-percentage-point greater reduction in A1C and less weight gain than those in the basal-bolus insulin therapy group.

FDA Approves New Diabetes Combo LixiLan and IDegLira for T2 Diabetes

Both products, known as LixiLan and IDegLira during clinical trials, were delayed by 3 months at the U.S. Food and Drug Administration (FDA) following recommendations for approval from FDA panels back in May. And yet the FDA has approved the two new competing combination products containing fixed doses of glucagonlike-peptide 1 (GLP-1) receptor agonists and […]

Long-acting Synjardy gets FDA approval for type 2 diabetes treatment in the US

The US Food and Drug Administration (FDA) has approved the slow release form of Synjardy. Synjardy is a drug used by people with type 2 diabetes in the UK as a twice daily single pill combination therapy to lower blood sugar levels.

Joslin Diabetes – Is it Possible to Get Diabetes from Statins?

If you’re like nearly one-third of Americans over age 40, you probably take a statin. These cholesterol-lowering drugs are used for reducing risk of stroke and heart attack. They work by lowering the amount of LDL cholesterol, the so-called “bad cholesterol” in the blood. Statins also reduce inflammation around plaque in the blood vessels.

Can Statins Offset Insulin-Related Cancer Risk in T2DM?

The researchers found that the risk of cancers of the colon (males only), liver (males only), pancreas, lung (males only), and brain (males only) were increased up to nine-fold for patients treated with insulin or insulin secretagogues; the risk of prostate cancer was decreased strongly. The risks were generally decreased for patients taking statins, with […]

Trial finds type 2 diabetes drug liraglutide can affect heart rate variability

The type 2 diabetes drug liraglutide could affect heart variability in newly diagnosed people who are overweight and have heart problems, according to new research. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which helps control blood sugar levels and reduces post-meal hyperglycemia. The drug is marketed as Victoza and Saxenda.

Diabetes Mine – Media Matters: The Feud Over Heart Risk Lowering Diabetes Drugs

Believe it or not, some people were disappointed and underwhelmed by solid evidence that Victoza (ligratude), a medication for type 2 diabetes, reduces the risk of fatal diabetes complications. That news, based on a massive clinical trial of Novo Nordisk’s drug, was one of the mostly widely reported items from the American Diabetes Association’s recent […]